A protocol for high-dose lisdexamfetamine and contingency management, alone or in combination, for the treatment of methamphetamine use disorder: The ASCME study
Paxton Bach(University of British Columbia), Didier Jutras-Aswad(Centre Hospitalier de l’Université de Montréal), Ginette Poulin(British Columbia Centre on Substance Use), Bernard Le Foll(Centre for Addiction and Mental Health), Hamzah Bakouni(Centre Hospitalier de l’Université de Montréal), Alexandra de Kiewit(Parks Canada)
Cited by 0
Related Papers
Genetics of dopamine receptors and drug addiction: a comprehensive review
|Behavioural Pharmacology|2009|396
Tobacco and nicotine use
|Nature Reviews Disease Primers|2022|293
Characterization of Environmental Sources of the Human and Animal Pathogen <i>Cryptococcus gattii</i> in British Columbia, Canada, and the Pacific Northwest of the United States
|Applied and Environmental Microbiology|2006|238
Identification of Dopamine D1–D3 Receptor Heteromers
|Journal of Biological Chemistry|2008|230
Methadone Matters: What the United States Can Learn from the Global Effort to Treat Opioid Addiction
|Journal of General Internal Medicine|2019|150